Shots:

• The BTD is based on P-II superiority trial assessing Exebacase + SOC antibiotic therapy vs SOC alone in patients with Staphylococcus aureus bacteremia- including endocarditis
• In a pre-specified analysis of the subgroup with MRSA infections- the clinical responder rate @day14 (74.1% vs 31.3%). The Exebacase demonstrated a reduction in the 30-day all-cause mortality- 4days reduction in length of hospital stay- and reductions in 30-day hospital readmission rates in MRSA-infected patients
• Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus

 ­ Ref: GlobeNewswire | Image: Exelixis